of Supplement Alzheimer's disease (AD) is a devastating condition affecting millions and costing hundreds of billions of dollars in caregiving expenses, for which no effective therapy exists. The pathophysiology of AD is complex and not fully understood, but nutrition and exercise represent the most significant lifestyle determinants of AD risk. Mitochondria have been linked to neurodegeneration on many levels; however, their DNA has not been carefully studied in the context of Alzheimer's disease risk. Our lab characterized humanin, a mitochondrial-derived peptide encoded from the 16S rRNA region of the mtDNA, which has shown to be a potent neuroprotective factor. We recently showed that humanin administration prevents age-dependent cognitive decline in mice, and others have shown that it slows the progression of amyloid beta (A?)-driven neurodegeneration in AD mouse models. In recent unpublished data presented in this grant, separately, we recently identified a SNP in the humanin ORF that is associated with lower circulating humanin levels and with more rapid cognitive decline in individuals followed in the Health and Retirement Study (HRS). We now propose to expand this paradigm to the entire mitochondrial genome to discover novel peptides that modulate AD and purpose the hypotheses that: 1) mitochondrial genetic variants interact with nutritional factors to modify ADRD risk and 2) the mitochondrial peptide transcriptome is dramatically affected by high-fat diet in aged mice. We will center our focus by conducting cutting-edge genetic analyses to first see if certain mtSNPs attenuate or synergize with diet to affect ADRD risk. This project will engage a team of scientists to address variation in mitochondrial DNA (Aim 1) and mitochondrial RNA (Aim 2) with diet using the Health and Retirement Study cohort and RNASeq data on brain samples from mice fed a high-fat diet, respectively. Altogether, this supplement will identify mtDNA variants and potential peptides that interact with diet to modify ADRD risk byusing two independent approaches (well characterized large human databases and state-of-the- art novel transcriptomic approaches). If successful, findings from this project could lead to new target identification of peptides with therapeutic potential.

Public Health Relevance

Poor nutrition is a risk factor for Alzheimer's disease (AD), a neurodegeneration condition that affects millions of people in the United States and costs hundreds of billions of dollars in caregiving expenses because no effective therapy exists. Unkown genetic factors may also be involved. Mitochondrial gene variants and expression are often ignored from genetic and transcriptomic analyses. Our group developed novel tools to study mitochondrial sequencing that could lead to the identification of novel therapeutic targets for precision ADRD care. Moreover, we believe our proposed studies are highly significant, allowing for more precise identification of at risk individuals that can be targeted for early intervention or prevention through specific nutritional approaches.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Research Program Projects (P01)
Project #
3P01AG055369-03S1
Application #
10123512
Study Section
Special Emphasis Panel (ZAG1)
Program Officer
Fridell, Yih-Woei
Project Start
2018-02-15
Project End
2023-01-31
Budget Start
2020-08-01
Budget End
2021-01-31
Support Year
3
Fiscal Year
2020
Total Cost
Indirect Cost
Name
University of Southern California
Department
Type
Other Specialized Schools
DUNS #
072933393
City
Los Angeles
State
CA
Country
United States
Zip Code
90089
Nashine, Sonali; Cohen, Pinchas; Nesburn, Anthony B et al. (2018) Characterizing the protective effects of SHLP2, a mitochondrial-derived peptide, in macular degeneration. Sci Rep 8:15175
Guidi, Novella; Longo, Valter D (2018) Periodic fasting starves cisplatin-resistant cancers to death. EMBO J 37:
Liang, Pei; Henning, Susanne M; Guan, Johnny et al. (2018) Role of Host GPR120 in Mediating Dietary Omega-3 Fatty Acid Inhibition of Prostate Cancer. J Natl Cancer Inst :
Qin, Qing; Mehta, Hemal; Yen, Kelvin et al. (2018) Chronic treatment with the mitochondrial peptide humanin prevents age-related myocardial fibrosis in mice. Am J Physiol Heart Circ Physiol 315:H1127-H1136
Yen, Kelvin; Wan, Junxiang; Mehta, Hemal H et al. (2018) Humanin Prevents Age-Related Cognitive Decline in Mice and is Associated with Improved Cognitive Age in Humans. Sci Rep 8:14212
Henning, Susanne M; Galet, Colette; Gollapudi, Kiran et al. (2018) Phase II prospective randomized trial of weight loss prior to radical prostatectomy. Prostate Cancer Prostatic Dis 21:212-220
Mao, Kai; Quipildor, Gabriela Farias; Tabrizian, Tahmineh et al. (2018) Late-life targeting of the IGF-1 receptor improves healthspan and lifespan in female mice. Nat Commun 9:2394
Kim, Su-Jeong; Mehta, Hemal H; Wan, Junxiang et al. (2018) Mitochondrial peptides modulate mitochondrial function during cellular senescence. Aging (Albany NY) 10:1239-1256
Xiao, Jialin; Cohen, Pinchas; Stern, Mariana Carla et al. (2018) Mitochondrial biology and prostate cancer ethnic disparity. Carcinogenesis 39:1311-1319
Nencioni, Alessio; Caffa, Irene; Cortellino, Salvatore et al. (2018) Fasting and cancer: molecular mechanisms and clinical application. Nat Rev Cancer 18:707-719